[Treatment of cerebrovascular deficiencies. Therapeutic evaluation from 129 cases using the double-blind method against placebo].
We report the results of a double-blind trial in 129 patients, most of whom were treated in geriatric centers. These results provide unequivocal evidence of the superiority of l-eburnamonine which improved 22 of the 25 parameters selected to assess superior brain functions, whereas only four parameters were bettered under placebo. Moreover, the action of Cervoxan is either stable or progressive. Lastly, clinical tolerance of this drug is excellent.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D010919:Placebos; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C016422:eburnamonine
Traitement des déficits cérébro-vasculaires. Evaluation thérapeutique à partir de 129 observations utilisant la méthode du double aveugle contre placebo.